

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

Recombinant Anti-F4/80 antibody [EPR26545-166]

RRID:AB_2936298

Type: Antibody

Proper Citation

Abcam Cat# ab300421, RRID:AB_2936298

Antibody Information

URL: http://antibodyregistry.org/AB_2936298

Proper Citation: Abcam Cat# ab300421, RRID:AB_2936298

Target Antigen: F4/80

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: ICC/IF, IHC-P, IHC-Fr, WB

Antibody Name: Recombinant Anti-F4/80 antibody [EPR26545-166]

Description: This recombinant monoclonal targets F4/80

Target Organism: rat, mouse

Clone ID: EPR26545-166

Antibody ID: AB_2936298

Vendor: Abcam

Catalog Number: ab300421

Record Creation Time: 20250819T235154+0000

Record Last Update: 20250820T063954+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-F4/80 antibody [EPR26545-166].

No alerts have been found for Recombinant Anti-F4/80 antibody [EPR26545-166].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang X, et al. (2025) Mechanical Force-Induced cGAS Activation in Carcinoma Cells Facilitates Splenocytes into Liver to Drive Metastasis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(8), e2401127.

He B, et al. (2025) Spatial regulation of glucose and lipid metabolism by hepatic insulin signaling. *Cell metabolism*, 37(7), 1568.

Wen H, et al. (2025) NRF2 activation in cancer cells suppresses immune infiltration into the tumor microenvironment. *iScience*, 28(10), 113519.

Sun X, et al. (2025) High-dose ascorbic acid selectively induces pyroptosis in LKB1-deficient lung cancer and sensitizes immunotherapy. *Cell reports. Medicine*, 6(9), 102291.

Yang S, et al. (2025) LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1/LTBP1/TGF- β axis. *Cell reports. Medicine*, 6(3), 102000.

Liu Y, et al. (2025) Muscle-derived small extracellular vesicles induce liver fibrosis during overtraining. *Cell metabolism*, 37(4), 824.

Xie M, et al. (2025) Gut symbiont-derived ursodeoxycholic acid promotes fatty acid oxidation to protect against renal ischemia-reperfusion injury. *Cell reports. Medicine*, 102373.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. *Cell*, 188(24), 6754.

Zhang YF, et al. (2025) A Novel TLR4 Inhibitor DB03476 Rescued Renal Inflammation in Acute Kidney Injury Model. *International journal of molecular sciences*, 27(1).

Huang Y, et al. (2024) Schwann cell promotes macrophage recruitment through IL-17B/IL-17RB pathway in injured peripheral nerves. *Cell reports*, 43(2), 113753.

Lu H, et al. (2024) The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. *Cell reports*, 43(1), 113587.

Wang S, et al. (2024) Region-specific cellular and molecular basis of liver regeneration after acute pericentral injury. *Cell stem cell*, 31(3), 341.

Bao X, et al. (2024) A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer. *Cell reports. Medicine*, 5(2), 101399.

Bai S, et al. (2024) Extracellular vesicles from alveolar macrophages harboring phagocytosed methicillin-resistant *Staphylococcus aureus* induce necroptosis. *Cell reports*, 43(7), 114453.

Sciarretta F, et al. (2024) Lipid-associated macrophages reshape BAT cell identity in obesity. *Cell reports*, 43(7), 114447.

Griesel BA, et al. (2024) PFKFB3 protein in adipose tissue contributes to whole body glucose homeostasis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 38(23), e70254.

Yang Z, et al. (2023) A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation. *EBioMedicine*, 92, 104594.

Osorio JC, et al. (2023) The antitumor activities of anti-CD47 antibodies require Fc-Fc γ R interactions. *Cancer cell*, 41(12), 2051.